OncoMatch/Clinical Trials/NCT06598007
A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors
Is NCT06598007 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies CT3001 for solid tumor, adult.
Treatment: CT3001 — This is an FIH, multicenter, open-label, dose escalation and dose expansion study of CT3001, which will be conducted in 2 phases: Phase 1 and Phase 2a. Phase 1 will be a standard 3+3 dose escalation and dose finding study in patients with advanced solid tumors for whom there is no available therapy (or patients are not candidates for such therapy) for the assessment of DLTs at up to 6 dose levels of CT3001. Phase 2a is a dose expansion study to evaluate the preliminary efficacy of CT3001 in patients with advanced CRC or PDAC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Colorectal Cancer
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy
solid tumors that are refractory to standard therapy, or for whom no standard therapy exists
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5 × 10^9/L without growth factor support in the 2 weeks prior to study entry. Hemoglobin ≥9.0 g/dL without transfusion, growth factor support, or other supportive medication in the 2 weeks prior to study entry. Platelet count ≥ 75 × 10^9/L without transfusion in 2 weeks prior to study entry.
Kidney function
Serum creatinine clearance (CrCL) > 60 mL/min, as per the Cockcroft-Gault Equation.
Liver function
Serum TBIL < 1.5 × ULN. AST and ALT < 3 × ULN.
Cardiac function
QTcF interval ≤ 470 ms (determined by average of 3 readings on triplicate 12-lead ECG); no history of additional risk factors for Torsade de Pointes (e.g., heart failure, hypokalemia, family history of long-QT syndrome) or current use of medications that prolong the QTcF interval.
Adequate hematologic, liver, and kidney function as follows: ... Coagulation tests: international normalized ratio (INR) < 1.5, activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN (Note: for those on oral anticoagulants, an INR in the range of 2 to 3 is acceptable). ... QTcF interval ≤ 470 ms ... no history of additional risk factors for Torsade de Pointes ... or current use of medications that prolong the QTcF interval.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify